SCNG and Cellontech Sign Joint Marketing Agreement for 'Katizol' with Dongkook Pharmaceutical

SC Engineering's subsidiary Cellontech announced on the 17th that it has signed a Memorandum of Understanding (MOU) with Dongkook Pharmaceutical for the joint marketing of ‘CartiZol’.

Under this MOU, Cellontech will produce three of the four CartiZol treatment options: △CartiZol Ultra (single-dose formulation), △CartiZol Active (three-dose formulation), and △CartiZol Prime (five-dose formulation), and supply them to Dongkook Pharmaceutical as the Ateborn series. The Ateborn series consists of three types: △Ateborn L (single-dose formulation), △Ateborn First (three-dose formulation), and △Ateborn (five-dose formulation).

Dongkook Pharmaceutical plans to further strengthen its market share in osteoarthritis, which has been increased through hyaluronic acid (HA) intra-articular injections Hyalon First and Hyalon Prefilled, by launching the Ateborn series in July. Ateborn carries the meaning of the ‘birth (Born)’ of a new osteoarthritis treatment option using medical collagen called ‘Atelocollagen’.

CartiZol is the first collagen intra-articular injection developed domestically by Cellontech. The main ingredient of CartiZol, bio-collagen, is registered in the U.S. Food and Drug Administration (FDA) Drug Master File (DMF). Unlike existing products, CartiZol, which supplements damaged articular cartilage with bio-collagen, a component of the synovial membrane, has differentiated competitiveness by not only relieving pain but also aiding the natural healing process of articular cartilage.

A Cellontech representative said, “Recent consecutive joint marketing agreements with leading domestic companies have proven CartiZol’s unique market competitiveness,” adding, “Based on CartiZol’s high therapeutic efficacy and various treatment options, we have been able to strategically and efficiently expand the sales network to contribute to increasing CartiZol sales.”

He continued, “With the synergy of Dongkook Pharmaceutical’s hospital and clinic network and sales and marketing capabilities, we can widely supply CartiZol to the market, and we will strive to establish it as a representative treatment option to improve quality of life in the ultra-aged society.”